This systematic review is to evaluate the efficacy and safety of Chinese herbal medicine (CHM) for people with insomnia. Randomized controlled trials (RCTs) investigating oral CHM alone or in combination with conventional therapies for primary insomnia were identified by searching English and Chinese publications and databases of clinical trial registration. Risk of bias was assessed according to the Cochrane Handbook 5.1. Meta-analysis was conducted using RevMan 5.2.4. Seventy-nine trials (7886 participants) were finally included in the review, and 76 were included in the meta-analysis. Twenty-seven trials reported the methods of random sequence generation, and five of them used the allocation concealment. Blinding of participants and personnel were used in 10 studies. The main meta-analysis showed that CHM alone was more effective than placebo by reducing scores of Pittsburgh Sleep Quality Index (mean difference, MD: −3.06, 95% confidence interval, CI: −5.14 to −0.98, I 2 = 97%) and benzodiazepine drugs (BZDs) (MD: −1.94, 95% CI: −2.45 to −1.43, I 2 = 96%). The effect was also seen when CHM was combined with BZDs compared with placebo plus BZDs (MD: −1.88, 95% CI: −2.78 to −0.97, I 2 = 0%) or cognitive and behavioral therapy (MD: −3.80, 95% CI: −4.91 to −2.68, I 2 = 68%) alone. There was no significant difference between CHM and placebo regarding the frequency of adverse events (relative risk, RR: 1.65, 95% CI: 0.67-4.10, I 2 = 0). Overall, oral CHM used as a monotherapy or as an adjunct to conventional therapies appears safe, and it may improve subjective sleep in people with insomnia. However, the typical effect of CHM for insomnia cannot be determined due to heterogeneity. Further study focusing on individual CHM formula for insomnia is needed. The development of a comparable placebo is also needed to improve the successful blinding in RCTs.
Introduction
Insomnia is a common sleep disorder. Around one-third of adults experience the symptoms of insomnia, and approximately 6% meet the diagnosis of insomnia worldwide [1] . Insomnia can result in functional impairment as well as increase the risk of severe conditions such as depression and cardiovascular disease in the long term [2, 3] . Growing evidence suggests that cognitive behavioral therapy for insomnia (CBT-i) is effective in improving subjective sleep outcomes [4] . However, it is underutilized in clinical practice because of difficulties in successful patient compliance [5] and high requirements of well-trained psychotherapists [6] . Pharmacotherapy such as benzodiazepine receptor agonists (BZRAs) is considered beneficial in improving sleep as well [7] . However, it is not without risks including tolerance and addiction from long-term use [8, 9] . Therefore, new treatments with low risk to benefit ratio are needed for insomnia.
Chinese herbal medicine (CHM), originating from ancient China, has been used to treat insomnia for >2000 years in China [10] . In modern China, both traditional herbal formulae and patent herbal products coexist in the treatment of insomnia [11] . Furthermore, conventional medicine and CHM are coadministered frequently in clinical practice for sleep disorders [12] [13] [14] [15] [16] . In recent years, CHM has been increasingly used as a form of complementary and alternative medicine (CAM) in the Western world such as in America, Europe, and Australia [17] . Although the mechanism by which CHM improves sleep is not fully elucidated, preclinical studies have shown that some Chinese herbal formulae or single herbal ingredients have sedative-hypnotic functions, which is mediated by the gammaaminobutyric acid-ergic (GABAergic) system [18] . For example, sour jujube seed (scientific name: Ziziphus spinosa Hu; pharmaceutical name: Semen Zizyphi Spinosae; and Chinese pinyin: suan zao ren) has been shown to enhance the activity of GABA, an inhibitory neurotransmitter, as a single herb [19] or as a main ingredient in a multiherb formulation (known as sour jujube seed decoction), which modulates specific sedative effects by selective binding to the GABA(A) receptors [20] .
The public perception of the benefit of CHM in improving overall sleep and the potential hypnotic effects in animal studies need to be supported through critical evaluation of the clinical evidence. Two previous systematic reviews concluded that there was insufficient evidence to support the efficacy of CHM for insomnia [21, 22] . However, the latest Chinese evidence-based guideline for insomnia acknowledges the importance of CHM [11] without specific data on the role of CHM in clinical management for insomnia. Considering the growing number of clinical trials for CHM in recent years, it is important to update the search and evaluation to provide the best available evidence for insomnia. This systematic review and meta-analysis of randomized controlled trials (RCTs) aims to answer four clinical questions for insomnia: (1) whether CHM is more effective than placebo; (2) whether CHM is more effective than conventional therapies such as BZRAs and psychotherapies; (3) whether the adjunct use of CHM provides better outcomes than conventional medicine alone; and (4) whether CHM is safe when used alone or in combination with conventional therapies. [23, 24] , Diagnostic and Statistical Manual of Mental Disorders (DSM) [25] , Chinese Classification and Diagnosis of Mental Disease (CCMD) [26] , International Classification of Diseases (ICD) [27] , and other current guidelines [12, 13, [28] [29] [30] .
Methods

Eligibility
2
Interventions and controls.
Intervention included oral CHM treatment prepared in any form such as decoction, granule, capsule, and tablet. Studies that evaluated CHM combined with conventional therapies were also eligible. The comparators included placebo, pharmacotherapy routinely used such as benzodiazepine drugs (BZDs) and non-benzodiazepine drugs (non-BZDs), and psychotherapy such as CBT-i and sleep hygiene education. When another treatment was combined with CHM, the adjunct needed to be the same as the control.
Outcomes.
The primary outcome was overall sleep quality measured by the Pittsburgh Sleep Quality Index (PSQI). PSQI is a well-validated and commonly used instrument for sleep quality assessment. The global scores (value range: 0-21 points) were calculated by its seven domains reported by patients, including subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medications, and daytime dysfunction [31] . Higher scores indicated poorer sleep quality. It was translated into 56 additional languages including Mandarin Chinese [32] . In the Chinese population, its minimal clinically important difference (MCID) for Chinese medicine therapy was estimated to be 1.75 points by the standard error of measurement method or 1.54 by the distribution-based method [33] . Therefore, it was used as the threshold to assess the generalization of results to clinical practice.
Secondary outcomes included the following: (1) the total scores of the Athens Insomnia Scale (AIS) [34] ; (2) the total scores of the Insomnia Severity Index (ISI) [35] ; (3) the patient-rated sleep parameters such as sleep-onset latency, total sleep duration, sleep efficiency (ratio of time asleep to time on bed), and frequency of early awakenings; (4) objective sleep parameters measured by polysomnography (PSG), such as sleep-onset latency, total sleep duration, sleep efficiency, and times or duration of awakening after sleep onset; (5) clinical global impression (CGI) including the Clinical Global Impression-Severity scale (CGI-S) and Clinical Global Impression-Improvement scale (CGI-I) [36] ; and (6) frequency and nature of adverse events. 
Exclusion criteria
Database search and study selection
Five English databases (Cochrane Library, PubMed, EMBASE, CINAHL, and AMED), four Chinese databases (CBM, CNKI, CQVIP, and Wanfang), and five clinical trial registration databases (ClinicalTrials.gov, ICTRP, ChiCTR, EU-CTR, and ANZCTR) were comprehensively searched in May 2014. The search terms are specified in the Appendix A.
Two researchers (XN and JS) searched and screened the studies by finding duplications, excluding irrelevant titles and abstracts, and then selecting eligible studies by reviewing full texts.
Data extraction and management
Two researchers (XN and FL) extracted data in the manner of double entry and checking using EpiData Software, version 3.1 (EpiData Association, Odense, Denmark). Basic characteristics and outcome data were extracted, including authors, year of publication, diagnostic instrument, disease duration, stage, sample size, age, gender, details of intervention and control, information of follow-up, outcomes, and adverse events. The data were exported from EpidData to Microsoft Excel 2010 to facilitate sorting. E-mails were sent to the authors for clarification if important data were unavailable, duplication was suspected, or when more than one article reported the same trial. Another researcher (JS) validated the final dataset and the translation into English.
Assessment of risk of bias in included studies
The risk of bias was appraised by two independent reviewers (XN and LZ) according to the Cochrane Collaboration's tool for assessing the risk of bias [37] . Seven domains were evaluated, including random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias. The assessment for blinding was made based on patient-reported outcomes (PROs) and clinician-reported outcomes (CROs). The objective sleep parameters rated by PSG were grouped as CROs because results can be affected by the assessors and assessment environments. Study protocols or registration information were used to help assess the risk of bias for selective reporting. The risk of other bias was judged by assessing baseline balance and funding source. Judgments were categorized as "low risk of bias," "high risk of biases," or "unclear risk of bias." Disagreement was resolved by discussion and consultation with a senior researcher (XG) when necessary.
Measures of treatment effect
Continuous outcomes were presented as mean difference (MD) with 95% confidence interval (CI) between two groups, whereas dichotomous data were presented as relative risk (RR) with 95% CI. RevMan software (Version 5.2.4, Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012) was used for data analysis.
For trials with more than one CHM intervention group such as CHM formula A versus CHM formula B versus pharmacotherapy, all relevant CHM groups were combined; for trials with more than one type of control such as CHM versus pharmacotherapy versus placebo, pair-wise comparison results were reported based on different class of comparators. When different outcomes for the same trial were reported in separate publications, the data were merged into one trial.
The predefined main comparisons in the meta-analysis were as follows: (1) CHM versus placebo, (2) CHM versus BZDs, (3) CHM versus non-BZDs, (4) CHM versus psychotherapy, (5) CHM plus BZDs versus placebo plus BZDs, (6) CHM plus non-BZDs versus placebo plus non-BZDs, (7) CHM plus psychotherapy versus placebo plus psychotherapy, (8) CHM plus BZDs versus BZDs, (9) CHM plus nonBZDs versus non-BZDs, and (10) CHM plus psychotherapy versus psychotherapy.
Subgroup analysis and solutions to heterogeneity
Clinical heterogeneity between trials for the primary outcome was addressed by further subgroup analysis noting important factors including treatment duration (≤4 weeks and >4 weeks), history of insomnia (<1 year and ≥1 year), and different preparations of CHM (decoction and non-decoction). Statistical heterogeneity was detected using a chi-squared test. The fixed-effect model was used to estimate the typical effect for studies with low heterogeneity (I 2 < 50%), whereas the random-effects model was used to estimate the average distribution for studies with substantial unexplained heterogeneity (I 2 ≥ 50%).
Sensitivity analysis
Blinding of participants and allocation concealment are important for the PRO results. The primary outcome (PSQI) was a PRO, and sensitivity analysis was performed by only including trials with low risk of bias for blinding of participants and allocation concealment.
In studies comparing CHM with pharmacotherapies, the sensitivity analysis of PSQI scores was performed by including studies that removed the sixth domain (use of medication) because participants in the pharmacotherapy group would score higher on this domain.
Imbalance baseline can suggest failure of randomization [38] . Another sensitivity analysis was conducted by excluding the studies with the imbalance baseline of PSQI scores.
Publication bias
Publication bias was assessed when the subgroup included >10 studies.
Results
Description of included studies
Search results
The primary search identified 47,391 articles in literature databases and seven records in registries. Seventy-nine RCTs with 7886 participants published in 81 articles were finally included in the systematic review . A total of 76 were also included in the meta-analyses 118] . The screening process is shown in Fig. 1 .
Basic characteristics of the included studies
All included studies were randomized, parallel-group, controlled trials conducted in China between 2003 and 2014. Seven were multiarm studies [48, 56, 77, 78, 83, 92, 110] , and the rest were twoarm studies. The treatment duration ranged from one week to three months (mean: 29 days, median: 29 days, mode: 28 days). Thirteen conducted follow-up ranging from one week to six months after the end of the treatment [43, 45, 63, 65, 80, 81, 87, 89, 100, 101, 103, 108, 116, 117] . Participants ranged in age from 15 to 84 years, and insomnia was diagnosed by CCMD-3 in 64 studies [39,40,42-48,50-56,58-71,73,74,77-80,82,84,85,87,89-92,94-96, 98-100,102,104-110,112-117,119] , ICSD-2 in six studies [41, 76, 93, 97, 103, 111] , ICD-10 in seven studies [49, 57, 72, 75, 81, 83, 101, 118] , DSM-4 in one study [88] , and Chinese national guideline in one study [86] . The duration of insomnia history ranged from one month to 30 years. The PSQI was reported in 59 studies [39-43,46-51,53-55,57,58,60-65,67,68,72-84,86-88,90-96, 98-104,106,108,109,111,114,119] , the AIS in eight studies [52, 56, 59, 66, 85, 97, 110, 115] , patient-rated sleep parameters in 13 studies [41, 44, 45, 50, 68, 69, 71, 80, 95, 103, 105, 112] , PSG-reported sleep parameters in two studies [76, 94] , and the CGI-S in four studies [70, 89, 107, 113] . The ISI and the CGI-I were not reported in any study. Twenty-six studies used Chinese patent herbal products [41, 48, 54, 58, 60, 64, 67, 71, 74, 75, [80] [81] [82] [83] 91, [93] [94] [95] [96] [99] [100] [101] 103, 104, 108, 111, 119] , and other studies used decoctions, the traditional form, and combination method. Sixty-six herbal formulae were investigated in the included studies. The most frequent formulae were Xue Fu Zhu YuTang (traditional decoction) and Zao Ren An Shen Capsule (patent product). The herb most commonly used was sour jujube seed. The complete characteristics of the included studies are shown in Tables 1 and 2 .
Risk of bias in the included studies
Only one study registered the protocol in ChiCTR [76] . The risk of bias for other studies was assessed based on their publications. Twenty-seven studies (34.18%) reported adequate methods of random sequence generation, including computer software [68, 76, 80, 81, 95, 101, 104] , random number table [40, 43, 48, 50, 53, 54, 57, 65, 69, 73, 77, 78, [82] [83] [84] 87, 88, 90, 93, 106, 108] , and drawing of lots [111] . Sequence allocation was concealed in five studies (6.33%) [68, 75, 80, 81, 95, 101] . Blinding of participants and personnel were performed in 10 studies (12.66%) [41, 63, 68, 76, 80, 81, 94, 95, 101, 104, 108] . Only one study (1.27%) used an independent outcome assessor [76] . Two studies (2.53%) had high dropout rate with unreported reasons, and they did not appropriately treat missing data [76, 87] . One study (1.27%) did not report its predefined primary outcome (PSQI scores) with unreported reason [112] . Three studies showed imbalance baseline (3.80%) [50, 82, 109] . Sixteen studies (20.25%) were supported by nonprofit institutions, such as by national scientific funding [75, 76, 95] or local scientific grant [43, [46] [47] [48] 64, 73, 77, 78, 84, 85, 87, 93, 111, 115] , and the rest did not declare the presence or absence of a conflict of interest and the funding sources. The risk of bias is summarized in Fig. 2 2 = 57%; n = three RCTs, 323 participants) [39, 65, 84] or psychotherapy (MD: −1.23, 95% CI: −2.48-0.01, n = one RCT, 120 participants) [92] . A four-arm, double-blind, double-dummy RCT (33 participants) reported that CHM plus placebo of BZDs was not superior to BZDs plus placebo of CHM (MD: −2.10, 95% CI: −6.00-1.80) or placebo of BZDs plus placebo of CHM (MD: −1.60, 95% CI: −4.45-1.25) [76] . The results are shown in Fig. 3 . At the end of follow-up ranging from 1 week to 3 months, CHM group had a significantly better effect on the PSQI scores than placebo (MD: −6.30, 95% CI: −12.58 to −0.02, I 2 = 97%; n = two RCTs, 158 participants) [63, 80] ,, BZDs (MD: −3.61, 95% CI: −5.81 to −1.40, I 2 = 97%; n = three RCTs, 228 participants) [87, 100, 103] , and non-BZDs (MD: −2.70, 95% CI: −3.33 to −2.07; n = one RCT, 124 participants) [65] . The results are showed in Supplementary Fig. S1 .
CHM plus conventional medicine versus control.
In terms of sleep quality assessed by the PSQI scores, the effect of CHM plus BZDs was significantly better than that of placebo plus BZDs (MD: −1.88, 95% CI: −2.78 to −0.97, I 2 = 0; n = three RCTs, 121 participants) [76, 104, 108] and BZDs alone (MD: −3.19, 95% CI: −4.40 to −1.99, I 2 = 89%; n = five RCTs, 462 participants) [48, 58, 79, 88, 109] . CHM plus psychotherapy was more effective than psychotherapy alone (MD: −3.80, 95% CI: −4.91 to −2.68, I 2 = 68%; n = three RCTs, 372 participants) [77, 78, 92, 111] . However, CHM plus non-BZDs was not superior to non-BZDs alone (MD: −1.15, 95% CI: −2.49-0.19; n = one RCT, 96 participants) [91] . One RCT (193 participants) reported that CHM plus sleep hygiene education was not superior to placebo plus sleep hygiene education (MD: −0.81, 95% CI: −2.26-0.64) [41] . The results are shown in Fig. 4 .
At the end of a 7-day follow-up, the effect of CHM plus BZDs on PSQI scores was not superior to placebo plus BZDs (MD: −1.43, 95% CI: −3.04-0.18; n = one RCT, 60 participants) [108] . The results are shown in Supplementary Fig. S2. 
Athens Insomnia Scale 3.3.2.1. CHM alone versus control.
In terms of global sleep quality evaluated by the AIS, CHM was more effective than BZDs (MD: −1.42, 95% CI: −2.21 to −0.64, I 2 = 63%; n = six RCTs, 463 participants) [52, 59, 66, 85, 97, 115] , but not more effective than non-BZDs (MD: 0.14, 95% CI: −0.26-0.54, I 2 = 0%; n = two RCTs, 121 participants) [56, 110] . The results are shown in Supplementary Fig. S3 .
CHM plus conventional medication versus control.
The effect of CHM plus non-BZDs on the AIS scores was similar to that of non-BZDs alone (MD: −0.57, 95% CI: −0.95 to −0.19, I 2 = 0%; n = two RCTs, 120 participants) [56, 110] . The results are shown in Supplementary Fig. S4. 
Patient-rated sleep parameters 3.3.3.1. Sleep-onset latency.
In terms of sleep-onset latency reported by patients, CHM was more effective than placebo (MD: −19.87 min, 95% CI: −26.93 to −12.82 min, I 2 = 0%; n = three RCTs, 395 participants) [68, 80, 95] , but not more effective than BZDs (MD: −13.81 min, 95% CI: −31.27-3.65 min, I 2 = 92%; n = three RCTs, 329 participants) [69, 103, 112] . There was no significant difference between the effect of CHM plus non-BZDs and non-BZDs alone (MD: −1.93 min, 95% CI: −11.30-7.44 min; n = one RCT, 60 participants) [71] or CHM plus sleep hygiene and BZDs plus sleep hygiene (MD: −2.81 min, 95% CI: −8.17-2.55 min; n = one RCT, 193 participants) [41] . The results are shown in Supplemental Figs. S5 and S6. At the end of a 3-month follow-up period, participants who received CHM reported shorter sleep-onset latency than those who received BZDs (MD: −32.00 min, 95% CI: −45.84 to −18.16 min; n = one RCT, 84 participants) [103] .
Total sleep duration.
In terms of total sleep duration reported by patients, CHM was more effective than placebo (MD: 0.78 h, 95% CI: 0.55-1.01 h, I 2 = 0%; n = three RCTs, 395 participants) [68, 80, 95] and BZDs (MD: 1.12 h, 95% CI: 0.36-1.87, I 2 = 95%; n = seven RCTs, 783 participants) [44, 45, 50, 69, 103, 105, 112] . The results are shown in Supplemental Fig. S7 . At the end of a 3-month follow-up period, participants who received CHM reported longer total sleep duration than those who received BZDs (MD: 1.60 h, 95% CI: 1.08-2.12 h; n = one RCT, 84 participants) [103] . 
Sleep efficiency.
In terms of sleep efficiency calculated from patient-reporting sleep parameters, CHM was superior to placebo (MD: 9.72%, 95% CI: 6.49-12.96%, I 2 = 0; n = two RCTs, 294 participants) [68, 95] and BZDs (MD: 19.02%, 95% CI: 18.13-19.92%, I 2 = 0; n = two RCTs, 249 participants) [68, 103, 112] . The results are shown in Supplemental Fig. S8 . At the end of a 3-month follow-up period, participants who received CHM reported improved sleep efficiency than those who received BZDs (MD: 20%, 95% CI: 11.23-28.77%; n = one RCT, 84 participants) [103] .
Sleep parameters measured by PSG
Sleep parameters measured by PSG were only reported in two RCTs. Data synthesis was not possible because the study design of these two studies varied. According to the only one RCT (96 participants) [94] , CHM was not superior to placebo for sleep-onset latency (MD: −1.12 min, 95% CI: −10.31-8.07 min), total sleep duration (MD: 20.33 min, 95% CI: −11.78-52.44 min), sleep efficiency (MD: 3.00%, 95% CI: −2.80-8.80%), or times of awakenings (MD: −0.74 times, 95% CI: −2.88-1.40 times). The four-arm, double-blind, and double-dummy RCT (n = 33 participants) [76] reported no significant difference in sleep-onset latency, total sleep duration, sleep efficiency, or times of awakenings among CHM plus placebo BZDs, BZDs plus placebo CHM, CHM plus BZDs, and placebo CHM plus placebo BZDs.
Clinician global impression
There was no significant difference in the severity of clinician global impression assessed by CGI-S between CHM and BZDs (MD: 0.10, 95% CI: −0.20-0.41, I 2 = 0%; n = three RCTs, 236 participants) [70, 89, 113] or between CHM plus BZDs and BZDs alone (MD: −0.47, 95% CI: −1.09-0.15; n = one RCT, 86 participants) [107] . The results are shown in Supplementary Fig. S9 . At the end of a 1-week followup period, the CGI-S score was lower in participants who received CHM than those who received BZDs (MD: −0.89, 95% CI: −1.41 to −0.37; n = one RCT, 100 participants) [89] .
Adverse events
Adverse events were monitored in 43 studies. Eleven of them found no adverse events for the whole study [42, 53, 59, 65, 66, 80, 88, 94, 95, 104, 108] . Data of 23 studies were available for the metaanalysis of frequency. There was no significant difference in the frequency of adverse events between CHM and placebo (RR: 1.65, 95% CI: 0.67-4.10, I 2 = 0; n = two RCTs, 400 participants) [68, 101] . The CHM group had fewer adverse events than the BZD group (RR: 0.15, 95% CI: 0.07-0.28, I 2 = 76%; n = 16 RCTs, 1802 participants) [40, [43] [44] [45] 50, 52, 54, 55, 61, 74, 89, 90, 93, 99, 115, 118] and the non-BZD group (RR: 0.11, 95% CI: 0.02-0.58, I 2 = 0; n = two RCTs, 199 participants) [39, 84] . The adjunct CHM treatment did not significantly increase the frequency of adverse events associated with nonBZDs (RR: 0.36, 95% CI: 0.10-1.27; n = one RCT, 96 participants; n = one RCT, 96 participants) [91] or the psychotherapy group (RR: 1.58, 95% CI: 0.08-30.90, I 2 = 73%; n = two RCTs, 372 participants) [41, 111] . These results are shown in Figs. 5 and 6 . The most frequent types of adverse events in CHM groups were digestive dysfunction such as indigestion and mild increased defecation, dizziness, fatigue, drowsiness, and dry mouth. However, none of the studies assessed whether the reported adverse events were associated with CHM. 
Other analysis
Subgroup analysis of the primary outcome
The subgroup analysis based on treatment duration (≤4 weeks or >4 weeks), insomnia history (<1 year or ≥1 year), and preparation of CHM (decoction or non-decoction) could not address the heterogeneity of meta-analysis for the PSQI scores. The results are shown in Table 3 .
Sensitivity analysis
Only four studies (582 participants) had low risk of bias relating to allocation concealment and blinding of participants [68, 80, 95, 101] . All four studies compared non-decoction CHM treatment (≤1 month) with placebo. At the end of the treatment, the PSQI score was lower in participants who received CHM treatment than those who received placebo (MD: −2.13, 95% CI: −3.92 to −0.35,
Eleven studies comparing CHM with BZDs clarified that they excluded the sixth domain (use of sleep medications) when calculating the total scores of PSQI [46, 47, 53, 55, 62, 67, 72, 87, 93, 98, 102] . The PSQI scores were significantly lower in the participants treated with CHM than in those with BZDs (MD: −1.46, 95% CI: −2.10 to −0.81, I 2 = 80%; n = 11 RCTs, 1046 participants).
Imbalance baseline of PSQI scores was found in three studies in two heterogeneous meta-analyses [50, 82, 109] . After excluding them, a greater reduction of PSQI scores was observed in the participants treated with CHM (MD: −1.93, 95% CI: −2.46 to −1.39, I 2 = 96%; n = 33 RCTs, 3255 participants) and CHM combined with BZDs (MD: −2.72, 95% CI: −3.91 to −1.53, I 2 = 85%; n = four RCTs, 402 participants) than in those with BZDs alone.
Post hoc analysis
The post hoc subgroup analysis on primary outcome was made to explore the estimated effect of individual formula. Four formulae were investigated more than twice in the included RCTs with PSQI scores. The PSQI scores were lower in the participants treated with the Zao Ren An Shen capsule (MD: 0.47, 95% CI: −0.43 to −1.36, I 2 = 85%; n = three RCTs, 240 participants) [54, 74, 83] , the Xue Fu Zhu Yu decoction (MD: −1.29, 95% CI: −2.09 to −0.49, I 2 = 0; n = two RCTs, 266 participants) [62, 102] , and the Wuling capsule (MD: −2.34, 95% CI: −3.45 to −1.23, I 2 = 96%; n = two RCTs, 148 participants) than in those with BZDs [64, 100] . There was no significant difference of PSQI scores after the treatment with the Tian Wang Bu Xin pill and BZDs (MD: −0.73, 95% CI: −2.87-1.42; I 2 = 88%; n = two RCTs, 146 participants) [46, 57] .
Publication bias
Only the comparison between CHM and BZDs in the metaanalysis of PSQI scores included >10 studies. The publication bias was not detected in either the visual funnel plot ( Supplementary  Fig. S10 ), Egger's test (p = 0.708) or Begger's test (p = 0.122).
Discussion
Evidence summary and applicability
In this study, we systematically reviewed 79 RCTs investigating a variety of CHM treatments for participants with insomnia. We also performed meta-analyses to estimate the efficacy of CHM on subjective sleep quality assessed by validated instruments, patientrated sleep parameters, clinician-reported severity, and PSG results, as well as to determine the safety of CHM. This systematic review provides up-to-date and comprehensive evidence of the efficacy and safety of CHM for insomnia. We also investigated the impact of different treatment strategies, subtypes of participants, various comparators, and methodological designs on the effect, which makes our results clinically meaningful. Overall, this systematic review and meta-analysis showed that CHM was superior to placebo and BZDs when used as a monotherapy and was superior to BZDs and psychotherapy alone as an adjunct therapy in terms of subjective sleep quality and quantity and safety. CHM was not associated with more benefit than non-BZDs, although the risks were less. These results suggest that CHM could be a promising alternative therapy with a good benefit-risk ratio. In this systematic review, the most homogeneous meta-analysis of primary outcome was the comparison of CHM plus BZDs with placebo CHM plus BZDs. It showed that the adjunct use of CHM resulted in a larger reduction of PSQI scores by 1.88 points, which was greater than the MCID of PSQI scores [33] . This result suggests that the estimated effect of CHM as a co-intervention to BZDs is relevant and potentially important to the insomnia patients in real clinical practice.
As this systematic review only included participants primarily diagnosed with insomnia, the evidence on CHM generated from this systematic review cannot be generalized to the population with comorbid insomnia or medication/substance-induced insomnia. In addition, the longest follow-up duration of the CHM treatment was 6 months; thus, the evidence of safety related to CHM could not be generalized to a longer therapy.
Overall completeness of evidence and clinical implications
A placebo effect is commonly observed for self-reported outcomes related to insomnia where placebo treatment significantly improved the total scores of PSQI by 2.0 points, increased total sleep duration by 23.0 min, and decreased sleep-onset latency by 15.1 min, compared with no treatment [120] . In this systematic review, our primary finding was that CHM was superior to placebo in terms of the improvement of PSQI scores, sleep-onset latency, total sleep duration, and sleep efficiency in participants with insomnia. In the sensitivity analysis, the positive trend of CHM was robust after the studies with inadequate randomization, allocation concealment, or insufficient blinding were removed. This study provides new evidence of the effect of CHM on subjective insomnia. This result also suggests that CHM could be an alternative treatment for individuals with insomnia when CBT-i or pharmacotherapies are unavailable in clinical settings.
Previous studies showed that short-term use of BZDs was effective for insomnia [8] . However, the risks and side effects associated with BZDs, such as daytime drowsiness and drug dependency, have been noted in both research and clinical practice [9, [121] [122] [123] . Another striking finding of our systematic review was that CHM was associated with more benefit in terms of subjective sleep quality, total sleep duration, and sleep efficiency than BZDs, and these results remained robust in sensitivity analysis. Furthermore, the metaanalysis indicated that the frequency of adverse events in participants treated with short-to-medium CHM was significantly lesser than that of participants treated with BZDs, and no serious adverse events were reported in any study. These results suggest that CHM might be an alternative to BZDs for individuals whose predominant complaint is dissatisfaction with overall sleep quality and total sleep quantity, although to what extent CHM was better than BZDs remains uncertain. However, CHM did not have a better effect than nonBZDs on subjective outcomes of insomnia, although it was associated with less adverse events.
Insomnia management is complex as a sequential or integrative approach is used, particularly for persistent and chronic insomnia [124, 125] . In this systematic review, we also investigated the addon effect of CHM on conventional medicine. The meta-analysis showed that the adjunct use of CHM to conventional medicine resulted in greater improvement of subjective sleep quality compared with BZDs, non-BZDs, and CBT-i. The highest level of evidence was attained from the homogeneous meta-analysis comparing CHM plus BZDs with BZDs plus placebo. In addition, the adjunct use of CHM to CBT or non-BZDs did not increase the adverse events in participants with insomnia. These results provide new knowledge that CHM could be used as a complementary therapy for insomnia patients with a predominant complaint of dissatisfaction with overall sleep quality.
Drug tolerance is commonly encountered in pharmacotherapies for insomnia [126] . Our systematic review showed that the effect of CHM was well sustained in the medium-to-long-term followup, and this effect was significantly better than placebo, BZDs, and non-BZDs in terms of PSQI scores. This result also adds new knowledge to the field.
This systematic review showed that there was no significant difference between CHM and BZRAs for increasing sleep-onset latency or for reducing clinician-rated severity. This indicates that the conscientious and judicious implementation of the CHM evidence is required in clinical practice because the effect of CHM on insomnia varies according to the outcome measurement.
There was insufficient evidence addressing two important clinical questions: (1) whether CHM was more beneficial than CBT-i for participants with insomnia and (2) whether CHM changed the insomnia electrophysiology detected by PSG.
Limitations and implications for research
Proper randomization and allocation to reduce the selection bias are necessary for an RCT. We noted that appropriate randomization methods were only used in 34.18% of studies, and adequate allocation concealment in 6.33%. The poor status of randomization may be due to the low methodological quality or low report quality. However, both are likely to exaggerate the estimate of efficacy [127, 128] . Therefore, prospective registration of clinical trials and improvement of reporting quality according to CONSORT statement for herbal interventions are required in the future to present full transparency for the study design, implementation, and dataanalysis [129] [130] [131] .
Insufficient blinding can also lead to overestimation of the effect size [128] . Although double blinding is encouraged in RCTs, it is difficult to practice it for herbal intervention because of the different shape, smell, taste, and administration of CHM products from pharmacotherapy. Considering this challenge, the efficacy of any CHM product should be assessed in the comparison with placebo before its effectiveness is evaluated by using pharmacotherapy as its comparator. Sixty-six different CHM treatments were found in the pool of RCTs, but only 13 of them used placebo as comparators and only 10 used blinding. This indicates that more RCTs using placebo and blinding are needed. In addition, only two RCTs used placebo to CHM decoction, which suggests that the research and development of a placebo to CHM decoction is need.
PROs such as PSQI and patient-rated sleep parameters directly measure the core treatment benefits from patients' perspective in a natural setting [132] , which have been comprehensively analyzed in this meta-analysis. However, the treatment effect on PROs is easily changed by insufficient allocation concealment and blinding [133] . In light of the difficulty in blinding RCTs for Chinese herbal intervention, the increasing use of CROs such as CGI-s and CGI-I performed by blinded assessors is needed to provide the overall assessment of insomnia progression. Sleep laboratory studies such as PSG and actigraphy should also be encouraged to explore the mechanism of CHM's action in sleep structures.
Heterogeneity across studies often results in unsuccessful metaanalysis [134] . In this systematic review, we included RCTs of various interventions to gain a broad perspective on the evidence regarding the use of CHM for insomnia, and this caused heterogeneity in some meta-analyses. In addition, clinical and methodological heterogeneity could not be well addressed by subgroup or sensitivity analysis. Therefore, most results presented in this systematic review were the average effects of CHM on insomnia estimated by a randomeffect model, rather than the typical effect. This solution to heterogeneity was based on the assumption that effect being estimated in different CHM treatments may not be identical, but it follows some distribution [135, 136] . We noted that the effect size of formulae varied in the post hoc analysis, which agreed with our assumption. Therefore, further comprehensive searches and appraisals of the evidence for each CHM formula for insomnia are needed in the future.
Agreements and disagreements with other reviews
A previous high-quality systematic review with meta-analysis on standardized CHM for insomnia also suggested that CHM was superior to placebo and safe for individuals with insomnia [21] . However, our study is different from the previous study in four main areas. First, the previous study used Jadad scale [137] to examine the study quality, and it concluded that the poor methodological quality of the studies limited their ability to draw definitive conclusions. However, the use of Jadad scale is increasingly discouraged because the total score is an unreliable assessment of validity [138] [139] [140] . We used Cochrane risk and bias instrument to assess the domain-specific methodological quality, thus avoiding this problem. Second, we conducted the search up to May 2014 and therefore collected more up-to-date evidence. Third, we only included the participants diagnosed by standard instruments of insomnia, whereas the previous review treated insomnia as a complaint, which results in a different generalized population. Fourth, we used a comprehensive list of sleep measurements as outcomes, which provides more information for clinical practice and research.
Conclusion
Overall, oral CHM alone or when combined with routine care can safely improve subjective sleep in people with insomnia. However, the typical effect of CHM cannot be determined when compared with BRADs and CBT-i due to heterogeneity. Further systematic review focusing on individual formula for insomnia is needed. The development of a comparable placebo to traditional decoction is encouraged as well to ensure the successful blinding in clinical trials. 
